Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance,
pharmacokinetics and potential activity of an investigational agent, HE3286, when
administered orally, daily for 28 days to patients with mild-to-moderate ulcerative colitis.